How do you sequence treatment options in mIDH1 AML?

IVO Bridge – Episode 4
In this video, Dr. Eytan Stein presents the sequencing of treatment options for IDH1 mutant AML, specifically discussing the use of ivosidenib, Azacitidine, and Venetoclax triplet therapy followed by ivosidenib maintenance.

Dr. Eytan Stein – Hematologist – Oncologist – Memorial Sloan Kettering Cancer Center, New York, USA